Outlook Therapeutics, Inc.
Ticker(s):
OTLK
Country:
Sector & Industry:
Business Overview
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.
Contact & Other Information
Number of Employees:
23
Website:
,
,
Outlook Therapeutics terminated a securities purchase agreement, amended its Restated Certificate of Incorporation to increase authorized shares, and held its 2025 annual meeting where stockholders voted on director elections, share issuance, and auditor ratification.